MYELOMA UK

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +4.7%

  £5,243,249 → £5,491,127

• Cash

  +20.1%

  £1,802,807 → £2,165,731

• Net assets

  -12%

  £8,794,466 → £7,740,922

• Employees

  +6.7%

  75 → 80

• Wages

  +14.8%

  £2,551,150 → £2,929,804

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. MYELOMA UK 2006-09-06 → present
2. THE INTERNATIONAL MYELOMA FOUNDATION (UK) 1998-10-23 → 2006-09-06

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Henderson Loggie LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Our financial position has remained strong throughout the year. We believe our operating model continues to be cost effective and robust, with ongoing efficient and effective delivery of our programmes and good initial progress on the new strategic plans. As we progress our strategy, we will continue to develop and improve services for our users.”

Significant events

• “Myeloma UK hosted round-table events in 2024, bringing together leading international experts.”
• “Myeloma UK successfully challenged multiple decisions that would have prevented people accessing promising new medicines, overturning these decisions again and again.”
• “DaraCyBorD, the first bespoke treatment for AL amyloidosis, was made available on the NHS in February after Myeloma UK's appeal against NICE's initial rejection.”
• “In July 2024, NICE agreed to review its initial decision on elranatamab, lifting all previous restrictions by October, following Myeloma UK's challenge.”
• “In November 2024, Myeloma UK and UK Myeloma Society lodged an appeal on the unfair withdrawal of IsaPD, leading to an independent panel agreeing to review the decision.”
• “Myeloma UK successfully convinced NICE to lift restrictions on the treatment teclistamab (Tevayli®).”
• “Myeloma UK was involved in 11 drug appraisal processes in total, repeatedly proving that people's experience counts.”
• “Myeloma UK continued to fund 10 research projects in 2024.”
• “Myeloma UK accredited 15 new hospitals and re-accredited seven more through its Clinical Service Excellence Programme (CSEP) in 2024.”
• “Myeloma UK launched a new online HCP Hub in 2024 for healthcare professionals, researchers and academics to learn, share insights and collaborate.”
• “Myeloma UK formed a new partnership with the Race Equality Foundation in 2024 to address health inequalities.”
• “Myeloma UK hosted its first Gala Dinner in almost a decade in May 2024, raising over £506,000.”
• “Ian Hensley completed a 190-mile coast-to-coast walk, raising £15,000 and was named ITV Anglia's Regional Fundraiser of the Year at the 2024 Pride of Britain Awards.”
• “Myeloma UK's groundbreaking Myeloma Awareness Week campaign in June led to 250,000 social post views and a 380% increase in website visits.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

13

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.